Smith+Nephew confirms failed merger talks with J&J and lowers full-year forecasts citing orthopaedic segment weakness. The medical devices sector faces headwinds in orthopaedics, reflecting broader demand challenges in elective procedures and hospital spending. Reduced guidance impacts near-term profitability for Smith+Nephew, potentially affecting investor confidence and operational flexibility.
3 articles
Smith+Nephew confirmed failed merger talks with Johnson & Johnson's orthopaedics unit due to leadership disagreements. Consequently, the company cut its full-year revenue and profit forecasts citing p
Smith+Nephew reduced its full-year revenue growth forecast to approximately 4% due to persistent weakness in US knee and hip implant demand. The company expects new product launches to cushion the imp
Smith+Nephew reported a 3.1% rise in underlying Q1 revenue to $1.5 billion, maintaining its annual outlook while announcing a $500 million share buyback amidst supply chain challenges.
ChemBrief